A detailed history of Rathbones Group PLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Rathbones Group PLC holds 156,896 shares of LLY stock, worth $123 Million. This represents 0.73% of its overall portfolio holdings.

Number of Shares
156,896
Previous 129,360 21.29%
Holding current value
$123 Million
Previous $117 Million 18.68%
% of portfolio
0.73%
Previous 0.66%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$772.14 - $960.02 $21.3 Million - $26.4 Million
27,536 Added 21.29%
156,896 $139 Million
Q2 2024

Aug 09, 2024

BUY
$724.87 - $909.04 $23.3 Million - $29.2 Million
32,152 Added 33.08%
129,360 $117 Million
Q1 2024

May 14, 2024

BUY
$592.2 - $792.28 $13.6 Million - $18.1 Million
22,886 Added 30.79%
97,208 $75.6 Million
Q4 2023

Feb 13, 2024

BUY
$525.19 - $619.13 $1.1 Million - $1.3 Million
2,100 Added 2.91%
74,322 $43.3 Million
Q3 2023

Nov 13, 2023

BUY
$434.7 - $599.3 $6.87 Million - $9.47 Million
15,803 Added 28.01%
72,222 $38.8 Million
Q2 2023

Aug 04, 2023

SELL
$350.74 - $468.98 $720,770 - $963,753
-2,055 Reduced 3.51%
56,419 $26.5 Million
Q1 2023

May 12, 2023

SELL
$310.63 - $364.82 $245,087 - $287,842
-789 Reduced 1.33%
58,474 $20.1 Million
Q4 2022

Feb 14, 2023

SELL
$321.55 - $374.67 $1.45 Million - $1.69 Million
-4,501 Reduced 7.06%
59,263 $21.7 Million
Q3 2022

Nov 03, 2022

SELL
$296.48 - $337.87 $2.9 Million - $3.31 Million
-9,789 Reduced 13.31%
63,764 $20.6 Million
Q2 2022

Aug 12, 2022

SELL
$278.73 - $327.27 $564,706 - $663,049
-2,026 Reduced 2.68%
73,553 $23.8 Million
Q1 2022

May 11, 2022

SELL
$234.69 - $291.66 $327,861 - $407,449
-1,397 Reduced 1.81%
75,579 $21.6 Million
Q4 2021

Feb 10, 2022

SELL
$224.85 - $279.04 $658,135 - $816,750
-2,927 Reduced 3.66%
76,976 $21.3 Million
Q3 2021

Nov 04, 2021

SELL
$221.6 - $272.71 $561,756 - $691,319
-2,535 Reduced 3.08%
79,903 $18.5 Million
Q2 2021

Jul 30, 2021

BUY
$180.55 - $233.54 $310,907 - $402,155
1,722 Added 2.13%
82,438 $18.9 Million
Q1 2021

May 14, 2021

SELL
$164.32 - $212.72 $133,263 - $172,515
-811 Reduced 0.99%
80,716 $15.1 Million
Q4 2020

Feb 11, 2021

SELL
$130.46 - $172.63 $214,345 - $283,631
-1,643 Reduced 1.98%
81,527 $13.8 Million
Q3 2020

Nov 13, 2020

BUY
$146.22 - $169.13 $159,087 - $184,013
1,088 Added 1.33%
83,170 $12.3 Million
Q2 2020

Aug 07, 2020

SELL
$136.42 - $164.18 $255,378 - $307,344
-1,872 Reduced 2.23%
82,082 $13.5 Million
Q1 2020

May 04, 2020

SELL
$119.05 - $147.35 $420,246 - $520,145
-3,530 Reduced 4.04%
83,954 $11.6 Million
Q4 2019

Feb 11, 2020

BUY
$106.92 - $132.43 $466,171 - $577,394
4,360 Added 5.25%
87,484 $11.5 Million
Q3 2019

Nov 13, 2019

BUY
$106.79 - $116.16 $300,079 - $326,409
2,810 Added 3.5%
83,124 $9.3 Million
Q2 2019

Aug 12, 2019

SELL
$110.79 - $129.32 $125,857 - $146,907
-1,136 Reduced 1.39%
80,314 $8.9 Million
Q1 2019

May 09, 2019

SELL
$111.31 - $131.02 $85,152 - $100,230
-765 Reduced 0.93%
81,450 $10.6 Million
Q4 2018

Feb 12, 2019

BUY
$105.9 - $118.64 $736,640 - $825,259
6,956 Added 9.24%
82,215 $9.51 Million
Q3 2018

Oct 12, 2018

SELL
$85.86 - $107.31 $28,763 - $35,948
-335 Reduced 0.44%
75,259 $8.08 Million
Q2 2018

Jul 16, 2018

SELL
$75.7 - $86.88 $426,948 - $490,003
-5,640 Reduced 6.94%
75,594 $6.45 Million
Q1 2018

Apr 06, 2018

SELL
$74.21 - $87.6 $165,859 - $195,786
-2,235 Reduced 2.68%
81,234 $6.29 Million
Q4 2017

Jan 24, 2018

SELL
$81.94 - $87.89 $360,617 - $386,803
-4,401 Reduced 5.01%
83,469 $7.05 Million
Q3 2017

Oct 24, 2017

BUY
$77.07 - $85.54 $6.77 Million - $7.52 Million
87,870
87,870 $7.52 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $747B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Rathbones Group PLC Portfolio

Follow Rathbones Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Rathbones Group PLC with notifications on news.